Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
OSUR Catalyst Timeline
Dated clinical, regulatory and corporate events for OraSure Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for OraSure Technologies, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How OSUR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every OSUR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boyd Steven KyleDirector | Grant/Award | 3,666 163,234 held | $4.43 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OSUR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.3 % (-88.9 %) | 2.14 M | 565.00 K | -81.51% ( -2.49 M) |
Ownership Trends
OSUR Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How OSUR ranks across every disease it competes in
OSUR News
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
OraSure Technologies reported a 14% increase in revenue for Q3 2026, reaching $30.9 million. The company's gross margin improved to 45.2%, reflecting operational efficiencies. New products, including the Colli-Pee®Dx and OraQuick® Ebola 2.0, saw initial orders. Looking ahead, OraSure anticipates continued revenue growth into 2027.
Read more →OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care
OraSure Technologies has joined the World Coalition on Sickle Cell Disease to enhance global efforts in early diagnosis and care for sickle cell disease. The Coalition aims to elevate the condition on the health agenda and improve services for affected individuals. OraSure will contribute its diagnostic expertise to strengthen connections between diagnosis and treatment.
Read more →OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
OraSure Technologies, Inc. will announce its third quarter 2026 financial results on November 9, 2026, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss these results. A webcast of the call will be available on their investor relations page.
Read more →OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies reported its Q2 2026 financial results, showing a 9.7% sequential revenue increase to $30.6 million. The company achieved FDA clearance for its Colli-Pee™•Dx urine collection device and received Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test. Despite these advancements, total revenues decreased by 2% year-over-year, and the company recorded a non-GAAP operating loss.
Read more →OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. The company will host a conference call at 5 p.m. Eastern Time to discuss these results. A webcast of the call will be available on their investor relations page and archived for one year.
Read more →OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
OraSure Technologies received Emergency Use Authorization for its second-generation OraQuick™ Ebola 2.0 Rapid Antigen Test. This test can detect all four Ebola viruses and is designed for use with both live patients and deceased individuals. The FDA authorization comes amid a significant outbreak in Central Africa, highlighting the urgent need for effective diagnostics.
Read more →OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, enabling at-home self-collection for STI testing. This advancement allows for convenient sample collection while maintaining sample integrity. The kit supports Roche's molecular diagnostic systems and aims to improve access for underserved populations, facilitating scalable testing and public health initiatives.
Read more →OraSure Announces First Quarter 2026 Financial Results
OraSure Technologies, Inc. reported a revenue of $27.9 million for Q1 2026, surpassing its guidance midpoint. The company highlighted gross margin expansion and a strong balance sheet, which positions it well for growth and potential acquisitions. OraSure aims to decentralize diagnostics to improve healthcare accessibility and affordability.
Read more →OraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the "Company" or "OraSure") contains certain "forward-looking statements" within the me
OraSure Technologies, Inc. has provided an investor update discussing its transformation strategy and financial performance. In Q1, the company reported a 4% growth in total revenue, demonstrating positive traction in its core business segments. The update highlights key operational improvements, including a focus on disciplined execution and the return to breakeven for its core business. Additionally, there is an optimistic outlook for growth driven by innovation and improved visibility into funding for critical testing programs.
Read more →OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. will announce its first quarter 2026 financial results during an earnings call scheduled for May 6, 2026. The call will take place at 5 p.m. ET and will be accessible via a webcast on the company's investor relations page. This event is part of OraSure's commitment to transparency and stakeholder engagement.
Read more →OraSure Technologies Appoints John D. Bertrand to its Board of Directors
OraSure Technologies has appointed John D. Bertrand as an independent director to its Board of Directors. His extensive experience in healthcare technology and AI-enabled diagnostics is expected to bolster the company's strategic initiatives. Additionally, OraSure plans to seek shareholder approval to declassify its Board at the upcoming 2026 Annual Meeting, reflecting its commitment to governance and shareholder engagement.
Read more →Strategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizing across U.S. a
OraSure is actively pursuing a focused strategy designed to enhance revenue growth and profitability, with several product launches on the horizon. The company's diagnostics segment is poised for expansion, leveraging existing infrastructures and improving efficiency through operational transitions. Despite facing challenges, including pressure from Altai Capital regarding board decisions, OraSure aims for a strong market position as health funding stabilizes and testing volumes recover post-2025.
Read more →OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
OraSure Technologies, Inc. is responding to Altai Capital's demands for board representation, emphasizing its commitment to shareholder value and upcoming milestones in 2026. The company has engaged extensively with Altai but has faced rejection of settlement proposals. OraSure's Board has been refreshed with new independent directors to guide the company through this critical phase.
Read more →OraSure Announces Fourth Quarter 2025 Financial Results
OraSure Technologies reported its Q4 2025 financial results, achieving revenue of $26.8 million, which surpassed expectations. The company is optimistic about growth in 2026, driven by anticipated regulatory clearances and new product launches. OraSure's CEO highlighted the stability in key segments and the company's strategic investments to enhance value.
Read more →OraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies has announced that its OraQuick HIV Self-Test has received licensing from Health Canada, making it the first oral HIV self-test available in Canada. The test allows individuals to determine their HIV status using a simple oral swab in just 20 minutes. This initiative aims to improve access to HIV testing and support public health efforts in combating the epidemic.
Read more →OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
OraSure Technologies, Inc. will hold its earnings conference call on February 25, 2026, at 5 p.m. ET to discuss its fourth quarter 2025 financial results and business developments. The call will be accessible via a webcast on the company's investor relations page, which will also archive the session afterward.
Read more →OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies has confirmed the receipt of director nominations from Altai Capital for the upcoming 2026 Annual Meeting of Stockholders. The nominations include Altai's founder, Rishi Bajaj. However, since interviewing Mr. Bajaj, OraSure's Board has appointed alternative candidates and has not engaged further with Altai. The Board has seen a significant refreshment with seven departures and three new independent members, aiming to enhance its oversight of growth and value creation.
Read more →OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies has submitted applications to the FDA for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, alongside its Colli-Pee™ urine collection device. These submissions aim to enhance accessibility and convenience in STI testing. The company anticipates significant market opportunities, although regulatory approvals and competition pose potential risks.
Read more →OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
OraSure Technologies has confirmed the intent of Altai Capital to nominate two candidates for election to its Board of Directors at the 2026 Annual Meeting. The company maintains a commitment to shareholder value and has engaged in dialogue with Altai, evaluating its founder, Rishi Bajaj, for board service. Despite not appointing him, OraSure has made efforts to enhance its Board and is actively pursuing innovation in diagnostics. The company remains well-positioned financially with substantial cash reserves and no debt as it strives for sustainable profitability.
Read more →